Adami (Janssen): ‘Esketamine antidepressant, an important result of years of research’

“Janssen has historically been committed to bringing therapeutic solutions to mental illnesses and some of the most disabling neurological diseases. For us it is a very important research area because they are branches of medicine where there is a real unmet need”. This was stated by Marina Adami, Therapeutic Area Medical Manager Janssen, on the occasion of the presentation to the press of Janssen’s new drug against major depression. “The drug presented today – he explained – goes precisely in this direction: it has been specifically designed for the treatment of major depression which has proved resistant to common therapeutic and pharmacological approaches. Esketamine is indicated precisely for those patients who cannot get out of major depressive episode with drugs that are currently available. We believe it is very important to offer patients always new and diversified possibilities, just as it is essential to guarantee clinicians innovative and effective tools and drugs. For decades we have been working to ensure that patient results can be the best possible and so that they can return to the life they deserve “.